James Harnett

Regeneron Pharmaceuticals, Inc.

Poster(s):

• (SLB-022) Concordance between blinded independent central review committee and physician-assessed responses: Analyses based on a real-world external control arm in relapsed/refractory multiple myeloma using IMWG data
  Monday, August 25, 2025

  11:45 AM - 12:45 PM ET

• (B-188) Safety and Effectiveness of Cemiplimab in Combination with Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: An Ongoing Real World Evidence Study
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET